<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7486822\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="of potential interactions in COVID19 patients receiving lopinavir/ritonavir (LPV/r). The" exact="secondary" post="objective was to develop recommendations and identify the risk"/>
  <result pre="Pâ€¯=â€¯.033), ICU admission (OR 9.22; CI 95% 1.98â€&quot;42.93; Pâ€¯=â€¯.005), previous" exact="respiratory" post="pathology (OR 2.90; 95% CI 1.15â€&quot;7.36; Pâ€¯=â€¯.024), psychiatric (OR"/>
  <result pre="CI 1.15â€&quot;7.36; Pâ€¯=â€¯.024), psychiatric (OR 4.14; 95 CI% 1.36â€&quot;12.61; Pâ€¯=â€¯.013)," exact="dyslipidemia" post="(OR 3.21; 95% CI 1.63â€&quot;6.35; Pâ€¯=â€¯.001) and the number"/>
  <result pre="with LPV/r is high, with age (&amp;gt;65), ICU admission, previous" exact="respiratory" post="and psychiatric pathology, dyslipidemia and the number of prescribed"/>
  <result pre="with age (&amp;gt;65), ICU admission, previous respiratory and psychiatric pathology," exact="dyslipidemia" post="and the number of prescribed drugs acting as risk"/>
  <result pre="la proteasa Introduction COVID-19 is the name given to the" exact="disease" post="caused by the &quot;Severe Acute Respiratory Syndrome Coronavirus 2&quot;"/>
  <result pre="the name given to the disease caused by the &quot;Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2&quot; (SARS-CoV-2), officially declared a global"/>
  <result pre="name given to the disease caused by the &quot;Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2&quot; (SARS-CoV-2), officially declared a global pandemic"/>
  <result pre="given to the disease caused by the &quot;Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2&quot; (SARS-CoV-2), officially declared a global pandemic by"/>
  <result pre="a protease inhibitor (PI), used in the treatment of human" exact="immunodeficiency" post="virus (HIV) infection.4 Lopinavir has antiviral activity, while ritonavir"/>
  <result pre="the population with the highest risk of suffering from severe" exact="disease" post="due to COVID-19 are patients over 60 years of"/>
  <result pre="years of age and with a medical history, such as" exact="cardiovascular" post="disease.1 The main objective of the study was to"/>
  <result pre="the potential interactions in COVID-19 patients receiving LPV/r therapy. The" exact="secondary" post="objective was to develop recommendations for each interaction according"/>
  <result pre="All patients older than 18 with hospital admission diagnosed with" exact="pneumonia" post="due to COVID-19 or with clinical suspicion, who received"/>
  <result pre="with LPV/r, were included in the study. All cases with" exact="acute" post="respiratory symptoms including, among other symptoms, fever, persistent cough,"/>
  <result pre="LPV/r, were included in the study. All cases with acute" exact="respiratory" post="symptoms including, among other symptoms, fever, persistent cough, odynophagia"/>
  <result pre="symptoms including, among other symptoms, fever, persistent cough, odynophagia or" exact="respiratory" post="distress and that met hospital admission criteria, were considered"/>
  <result pre="were considered as suspected COVID-19 patients. The diagnosis of COVID-19" exact="pneumonia" post="was confirmed by positive PCR in a nasopharyngeal swab"/>
  <result pre="the electronic clinical history. Finally, 361 patients with hospital admission" exact="secondary" post="to COVID-19 pneumonia under treatment with LPV/r were included"/>
  <result pre="history. Finally, 361 patients with hospital admission secondary to COVID-19" exact="pneumonia" post="under treatment with LPV/r were included in the analysis."/>
  <result pre="n (%) Mean age 62.77â€¯Â±â€¯14.67 (21âˆ’98) Sex (male) 215 (59.6)" exact="Severe" post="(admitted to ICU) 44 (12) Previous illness Â Cardiovasculara"/>
  <result pre="ICU) 44 (12) Previous illness Â Cardiovasculara 165 (45.7) Â" exact="Dyslipidemia" post="114 (31.6) Â Cancer 51 (14.1) Â Gastrointestinal 47"/>
  <result pre="illness Â Cardiovasculara 165 (45.7) Â Dyslipidemia 114 (31.6) Â" exact="Cancer" post="51 (14.1) Â Gastrointestinal 47 (13) Â Respiratory 45"/>
  <result pre="(31.6) Â Cancer 51 (14.1) Â Gastrointestinal 47 (13) Â" exact="Respiratory" post="45 (12.5) Â Genitourinary 42 (11.6) Â Diabetes mellitus"/>
  <result pre="(14.1) Â Gastrointestinal 47 (13) Â Respiratory 45 (12.5) Â" exact="Genitourinary" post="42 (11.6) Â Diabetes mellitus 41 (11.4) Â Psychiatric"/>
  <result pre="(13) Â Respiratory 45 (12.5) Â Genitourinary 42 (11.6) Â" exact="Diabetes mellitus" post="41 (11.4) Â Psychiatric 41 (11.4) Â Neurological 29"/>
  <result pre="(11.4) Â Psychiatric 41 (11.4) Â Neurological 29 (8) Â" exact="Renal" post="f. 21 (5.8) Â Anaemia 16 (4.4) Â Autoimmune"/>
  <result pre="Â Renal f. 21 (5.8) Â Anaemia 16 (4.4) Â" exact="Autoimmune" post="15 (4.2) Renal f.: renal failure; LPV/r: lopinavir/ritonavir; ICU:"/>
  <result pre="21 (5.8) Â Anaemia 16 (4.4) Â Autoimmune 15 (4.2)" exact="Renal" post="f.: renal failure; LPV/r: lopinavir/ritonavir; ICU: intensive care unit."/>
  <result pre="Â Anaemia 16 (4.4) Â Autoimmune 15 (4.2) Renal f.:" exact="renal failure;" post="LPV/r: lopinavir/ritonavir; ICU: intensive care unit. aArterial hypertension (HT)"/>
  <result pre="f.: renal failure; LPV/r: lopinavir/ritonavir; ICU: intensive care unit. aArterial" exact="hypertension" post="(HT) was included in the cardiovascular history. A total"/>
  <result pre="intensive care unit. aArterial hypertension (HT) was included in the" exact="cardiovascular" post="history. A total of 3931 prescription lines were analysed"/>
  <result pre="aArterial hypertension (HT) was included in the cardiovascular history. A" exact="total" post="of 3931 prescription lines were analysed during admission, with"/>
  <result pre="home drugs, with a mean of 2.47â€¯Â±â€¯2.85 (0â€&quot;17) medications/patient. A" exact="total" post="of 369 potential interactions were recorded with 52 different"/>
  <result pre="CYP3A4 inhibition. QT prolongation â†‘ Dc. Cardiovascular toxicity risk, ventricular" exact="arrhythmia" post="(TdP) Contraindicated. Consider change to metoclopramide Antidiabetic Â Glibenclamide"/>
  <result pre="2 (0.54) CYP3A4 and 2D6 inhibitionb â†‘ Dc. Risk of" exact="hypoglycaemia" post="Reduce dosage. Monitor glucose. Â Gliclazide C 1 (0.27)"/>
  <result pre="of CYP3A4 and OATP1B1 transporter inhibition. â†‘ Dc. Risk of" exact="hypoglycaemia" post="Reduce dosage. Monitor glucose. Â Canagliflozin D 1 (0.27)"/>
  <result pre="5 (1.36) CYP3A4 inhibition. P-glycoprotein inhibition â†‘ Dc. Risk of" exact="bleeding" post="Change to LMWH at therapeutic doses. Â Rivaroxaban X"/>
  <result pre="Â Ticagrelor X 2 (0.54) CYP3A4 inhibition Dc. Risk of" exact="bleeding" post="Contraindicated. Switch to ASA monotherapy, switch to prasugrel (dual"/>
  <result pre="CYP3A4 inhibition. Prolonged PR â†‘ Dc. Risk of hypotension and" exact="AV block" post="Reduce dose 50%. Monitor BP and ECG. Â Nifedipine"/>
  <result pre="Contraindicated. Change to amlodipine with a 50% dose reduction. Other" exact="cardiovascular" post="drugs Â Digoxin D 2 (0.54) P-glycoprotein inhibition. Prolonged"/>
  <result pre="inhibition. QT prolongation â†‘ Dc. Risk of bradycardia, hypotension, ventricular" exact="arrhythmia" post="(TdP) Contraindicated. Antiarrhythmics Â Amiodarone X 5 (1.36) CYP3A4"/>
  <result pre="(1.36) CYP3A4 inhibition. QT prolongation â†‘ Dc. Risk of ventricular" exact="arrhythmia" post="Contraindicated. Close monitoring, ECG Â Flecainide X 1 (0.27)"/>
  <result pre="2 (0.54) CYP3A4 inhibition. Prolonged PR â†‘ Dc. Risk of" exact="AV block," post="bradycardia and increased negative inotropic effect Reduce dosage. ECG."/>
  <result pre="Â Atorvastatin D 26 (7.07) CYP3A4 inhibition â†‘ Dc. Risk" exact="of liver" post="toxicity and rhabdomyolysis Maximum dose 20 mg Â Lovastatin"/>
  <result pre="(7.07) CYP3A4 inhibition â†‘ Dc. Risk of liver toxicity and" exact="rhabdomyolysis" post="Maximum dose 20 mg Â Lovastatin X 1 (0.27)"/>
  <result pre="(0.82) BCRP and OATP1B1 transporter inhibition Maximum dose 10 mg" exact="Urological" post="Â Tamsulosin X 18 (4.89) CYP3A4 and 2D6 inhibitionb"/>
  <result pre="Methylprednisolone D 23 (6.25) CYP3A4 inhibition â†‘ Dc. Risk of" exact="Cushing's syndrome" post="Reduce dose Â Prednisone C 5 (1.36) Â Dexamethasone"/>
  <result pre="D 23 (6.25) CYP3A4 inhibition â†‘ Dc. Risk of Cushing's" exact="syndrome" post="Reduce dose Â Prednisone C 5 (1.36) Â Dexamethasone"/>
  <result pre="(1.63) CYP3A4 inhibition. QT prolongation â†‘ Dc. Risk of ventricular" exact="arrhythmia" post="(TdP) If GFR 30âˆ’60â€¯ml/min, reduce dose to 500â€¯mg/24â€¯h If"/>
  <result pre="CYP3A4 and 2D6 inhibitionb â†&quot; AMC. Decreased oestrogen modulating effect" exact="Muscle" post="relaxants Â Fentanyl iv D 4 (1.09) CYP3A4 inhibition"/>
  <result pre="iv D 4 (1.09) CYP3A4 inhibition â†‘ Dc. Risk of" exact="respiratory" post="depression Reduce dose to 25âˆ’50â€¯mcg/h. Monitor pain (ANI, NOL)"/>
  <result pre="D 4 (1.09) CYP3A4 inhibition â†‘ Dc. Risk of respiratory" exact="depression" post="Reduce dose to 25âˆ’50â€¯mcg/h. Monitor pain (ANI, NOL) Â"/>
  <result pre="Â Midazolam iv D 24 (6.52) â†‘ Dc. Risk of" exact="respiratory" post="depression and excess sedation. Do not exceedâ€¯&amp;gt;â€¯25â€¯mg/kg/h). Monitor depth"/>
  <result pre="Midazolam iv D 24 (6.52) â†‘ Dc. Risk of respiratory" exact="depression" post="and excess sedation. Do not exceedâ€¯&amp;gt;â€¯25â€¯mg/kg/h). Monitor depth of"/>
  <result pre="2 (0.54) CYP3A4 inhibition â†‘ Dc. Risk of sedation and" exact="respiratory" post="depression. Reduce dose Â Oxycodone D 1 (0.27) CYP3A4"/>
  <result pre="CYP3A4 and 2D6 inhibitionb â†‘ Dc. Risk of sedation and" exact="respiratory" post="depression. Anticonvulsants Â Carbamazepine D 1 (0.27) CYP3A4 inhibition"/>
  <result pre="of CYP3A4 and P-glycoprotein â†‘ Dc. Risk of sedation and" exact="respiratory" post="depression. Start low dose and increase as needed. Â"/>
  <result pre="QT prolongation. â†‘ Dc. CNS toxicity risk. Risk of ventricular" exact="arrhythmia" post="(TdP) Avoid in the elderly. Reduce dosage. Monitor CNS"/>
  <result pre="inhibition. QT prolongation â†‘ Dc. Risk of CNS, gastric and" exact="cardiovascular" post="toxicity. Reduce 50%âˆ’75% dose [0.1âˆ’6]Inhaled therapy Â Budesonide D"/>
  <result pre="Budesonide D 42 (11.41) CYP3A4 inhibition â†‘ Dc. Risk of" exact="Cushing's syndrome." post="Maximum dose 2 inhalations/12â€¯h. Consider beclomethasone Â Fluticasone D"/>
  <result pre="QT prolongation â†‘ Dc. Cardiovascular toxicity risk: tachycardia and ventricular" exact="arrhythmia" post="(TdP) Contraindicated. Consider salbutamol Antihistamines Â Ebastine D 1"/>
  <result pre="and headache Reduce dosage. Consider dexchlorpheniramine ASA: acetylsalicylic acid; ANI:" exact="analgesia" post="nociception index; AV: atrioventricular; Dc: drug concentration; AMC: active"/>
  <result pre="nociception index level; PR: PR interval; QT: QT interval; CNS:" exact="central nervous system;" post="BP: blood pressure; TdP: torsade de pointes; UGT: UDP-glucuronyl"/>
  <result pre="admission to ICU (OR 9.22; 95% CI 1.98â€&quot;42.93; Pâ€¯=â€¯.005), previous" exact="respiratory" post="disease (OR 2.90; 95% CI 1.15â€&quot;7.36; Pâ€¯=â€¯.024), psychiatric disease"/>
  <result pre="to ICU (OR 9.22; 95% CI 1.98â€&quot;42.93; Pâ€¯=â€¯.005), previous respiratory" exact="disease" post="(OR 2.90; 95% CI 1.15â€&quot;7.36; Pâ€¯=â€¯.024), psychiatric disease (OR"/>
  <result pre="Pâ€¯=â€¯.005), previous respiratory disease (OR 2.90; 95% CI 1.15â€&quot;7.36; Pâ€¯=â€¯.024)," exact="psychiatric disease" post="(OR 4.14; 95% CI 1.36â€&quot;12.61; Pâ€¯=â€¯.013), dyslipidaemia (OR 3.21;"/>
  <result pre="previous respiratory disease (OR 2.90; 95% CI 1.15â€&quot;7.36; Pâ€¯=â€¯.024), psychiatric" exact="disease" post="(OR 4.14; 95% CI 1.36â€&quot;12.61; Pâ€¯=â€¯.013), dyslipidaemia (OR 3.21;"/>
  <result pre="(vs. no) 66 (18.2) 61 (27.1) 9.75 (3.8âˆ’24.95) .000 Previous" exact="disease" post="(vs. no) Â Cardiovascular 165 (45.7) 133 (59.1) 4.71"/>
  <result pre="Â Cardiovascular 165 (45.7) 133 (59.1) 4.71 (2.92âˆ’7.57) .000 Â" exact="Dyslipidemia" post="114 (31.6) 96 (42.7) 4.87 (2.78âˆ’8.55) .000 Â Respiratory"/>
  <result pre="Â Dyslipidemia 114 (31.6) 96 (42.7) 4.87 (2.78âˆ’8.55) .000 Â" exact="Respiratory" post="45 (12.5) 37 (16.4) 3.15 (1.42âˆ’6.98) .005 Â Genitourinary"/>
  <result pre="Â Respiratory 45 (12.5) 37 (16.4) 3.15 (1.42âˆ’6.98) .005 Â" exact="Genitourinary" post="42 (11.6) 33 (14.7) 2.42 (1.12âˆ’5.24) .024 Â Diabetes"/>
  <result pre="Â Genitourinary 42 (11.6) 33 (14.7) 2.42 (1.12âˆ’5.24) .024 Â" exact="Diabetes mellitus" post="41 (11.4) 36 (16) 4.99 (1.9âˆ’13.05) .001 Â Psychiatric"/>
  <result pre="therapy. We are facing a new scenario with a different" exact="disease" post="profile, therefore, it is complex to make comparisons between"/>
  <result pre="it is complex to make comparisons between COVID-19 and other" exact="infections" post="such as HIV, where there is more experience with"/>
  <result pre="highest rate of interaction with LPV/r in our cohort. Therefore," exact="respiratory" post="disease was a risk factor associated with developing interactions."/>
  <result pre="rate of interaction with LPV/r in our cohort. Therefore, respiratory" exact="disease" post="was a risk factor associated with developing interactions. Another"/>
  <result pre="interactions. Another comorbidity with a high probability of interaction was" exact="psychiatric disorder." post="A group of drugs commonly involved in potential interactions"/>
  <result pre="Almost half of the patients in our study had a" exact="cardiovascular" post="history. This high prevalence is explained by the fact"/>
  <result pre="high prevalence is explained by the fact that we include" exact="arterial hypertension" post="within this group. COVID-19 infection is associated with haemostasis"/>
  <result pre="prevalence is explained by the fact that we include arterial" exact="hypertension" post="within this group. COVID-19 infection is associated with haemostasis"/>
  <result pre="fact that we include arterial hypertension within this group. COVID-19" exact="infection" post="is associated with haemostasis abnormalities, which may imply an"/>
  <result pre="haemostasis abnormalities, which may imply an increased risk of thromboembolic" exact="cardiovascular" post="disease.18 Therefore, it is recommended to maintain anticoagulation and"/>
  <result pre="and antiplatelet therapy as long as they are not associated" exact="with bleeding" post="episodes. The appropriate LPV/r-compatible, anticoagulant, or antiplatelet agent, should"/>
  <result pre="antiplatelet therapy as long as they are not associated with" exact="bleeding" post="episodes. The appropriate LPV/r-compatible, anticoagulant, or antiplatelet agent, should"/>
  <result pre="COVID 19, also prolong QT, increasing the risk of ventricular" exact="arrhythmia" post="(torsade de pointes). Therefore, the QT interval should be"/>
  <result pre="factors, avoiding drugs that prolong QT as much as possible.20" exact="Dyslipidemia" post="was another independent variable associated with developing potential interactions"/>
  <result pre="the highest rate of interaction, responsible for the previous association." exact="Hypercholesterolemia" post="and PI-statin interaction are also recurrent in HIV patients.21"/>
  <result pre="for the previous association. Hypercholesterolemia and PI-statin interaction are also" exact="recurrent" post="in HIV patients.21 On the other hand, there is"/>
  <result pre="statins are beneficial or harmful in COVID-19. Therefore, because prior" exact="cardiovascular disease" post="is associated with a worse prognosis of COVID-19,22 the"/>
  <result pre="are beneficial or harmful in COVID-19. Therefore, because prior cardiovascular" exact="disease" post="is associated with a worse prognosis of COVID-19,22 the"/>
  <result pre="statins in the immune response23 and their prior benefit in" exact="viral" post="pneumonia,24 it may be possible to consider keeping statins"/>
  <result pre="potential interactions, with age (&amp;gt;65), admission to the ICU, previous" exact="respiratory" post="disease and psychiatric disorders, dyslipidaemia and the number of"/>
  <result pre="interactions, with age (&amp;gt;65), admission to the ICU, previous respiratory" exact="disease" post="and psychiatric disorders, dyslipidaemia and the number of drugs"/>
  <result pre="inhibitorsClin Pharmacokinet.52201381583110.1007/s40262-013-0075-423703578 22ZhouF.YuT.DuR.FanG.LiuY.LiuZ.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="Lancet.3951022920201054106210.1016/S0140-6736(20)30566-3 23YuanS.Statins may decrease the fatality rate of middle east" exact="respiratory" post="syndrome infectionmBio.62015e011201510.1128/mBio.01120-1526265720 24VandermeerM.L.ThomasA.R.KamimotoL.ReingoldA.GershmanK.MeekJ.Association between use of statins and mortality"/>
  <result pre="23YuanS.Statins may decrease the fatality rate of middle east respiratory" exact="syndrome" post="infectionmBio.62015e011201510.1128/mBio.01120-1526265720 24VandermeerM.L.ThomasA.R.KamimotoL.ReingoldA.GershmanK.MeekJ.Association between use of statins and mortality among"/>
 </snippets>
</snippetsTree>
